← Back to Clinical Trials
Recruiting NCT06337227

NCT06337227 Potential Role of Sirtuins As Epigenetic Biomarkers of the Patient with Atherosclerosis or Calcific Aortic Stenosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06337227
Status Recruiting
Phase
Sponsor IRCCS SYNLAB SDN
Condition Atherosclerosis and Calcific Aortic Stenosis with and Without Diabetes
Study Type OBSERVATIONAL
Enrollment 3 participants
Start Date 2023-10-19
Primary Completion 2025-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
lncRNA signature analyses

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3 participants in total. It began in 2023-10-19 with a primary completion date of 2025-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The project aims to shed light on the role of Sirtuins, enzymes belonging to the third class of histone deacetylases (class III) involved in epigenetic modifications (deacetylation), focusing mainly on Sirtuin 6 (SIRT6), as a regulator of atherosclerosis and severe aortic valve stenosis through molecular-based and epigenetic studies in human VSMC cells.

Eligibility Criteria

Inclusion Criteria: * Patients with atherosclerosis or calcific aortic stenosis with and without diabetes older than 18 years of either sex; * Patients without atherosclerosis undergoing surgical procedure for endocarditis; * Patients who will have signed informed consent Exclusion Criteria: * Patients for whom biological material cannot be recovered for study purposes; * Patients who refuse to participate in the study

Frequently Asked Questions

Who can join the NCT06337227 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atherosclerosis and Calcific Aortic Stenosis with and Without Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06337227 currently recruiting?

Yes, NCT06337227 is actively recruiting participants. Visit ClinicalTrials.gov or contact IRCCS SYNLAB SDN to inquire about joining.

Where is the NCT06337227 trial being conducted?

This trial is being conducted at Naples, Italy.

Who is sponsoring the NCT06337227 clinical trial?

NCT06337227 is sponsored by IRCCS SYNLAB SDN. The trial plans to enroll 3 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology